- Home
- PRI vs BBIO Comparison
PRI vs BBIO Comparison
Compare PRI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRI
- BBIO
- Stock Information
- Founded
- PRI 1927
- BBIO 2015
- Country
- PRI United States
- BBIO United States
- Employees
- PRI N/A
- BBIO N/A
- Industry
- PRI Life Insurance
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PRI Finance
- BBIO Health Care
- Exchange
- PRI Nasdaq
- BBIO Nasdaq
- Market Cap
- PRI 8.6B
- BBIO 9.4B
- IPO Year
- PRI N/A
- BBIO 2019
- Fundamental
- Price
- PRI $266.10
- BBIO $53.24
- Analyst Decision
- PRI Buy
- BBIO Strong Buy
- Analyst Count
- PRI 7
- BBIO 16
- Target Price
- PRI $316.00
- BBIO $65.25
- AVG Volume (30 Days)
- PRI 135.5K
- BBIO 1.8M
- Earning Date
- PRI 11-05-2025
- BBIO 11-11-2025
- Dividend Yield
- PRI 1.56%
- BBIO N/A
- EPS Growth
- PRI 61.36
- BBIO N/A
- EPS
- PRI 20.26
- BBIO N/A
- Revenue
- PRI $3,220,913,000.00
- BBIO $235,812,000.00
- Revenue This Year
- PRI $4.38
- BBIO $115.12
- Revenue Next Year
- PRI $5.62
- BBIO $65.29
- P/E Ratio
- PRI $13.17
- BBIO N/A
- Revenue Growth
- PRI 7.56
- BBIO 7.62
- 52 Week Low
- PRI $230.98
- BBIO $21.72
- 52 Week High
- PRI $307.91
- BBIO $57.49
- Technical
- Relative Strength Index (RSI)
- PRI 45.88
- BBIO 48.75
- Support Level
- PRI $262.06
- BBIO $53.72
- Resistance Level
- PRI $274.01
- BBIO $56.33
- Average True Range (ATR)
- PRI 6.32
- BBIO 1.71
- MACD
- PRI -0.82
- BBIO -0.25
- Stochastic Oscillator
- PRI 33.03
- BBIO 22.54
About PRI Primerica Inc.
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has three segments Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the United States.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.